Treatment of Central Precocious Puberty
Treatment of Central Precocious Puberty
复制标题
DOI：
10.1210/js.2019-00036
复制
发表时间：
2019-05-01
影响因子：
4.1
通讯作者：
Eugster, Erica A.
中科院分区：
文献类型：
--
作者：
Eugster, Erica A.
GnRH长效类似物（GnRHas）一直是全球中枢性性早熟（CPP）治疗的金标准，并具有令人羡慕的安全性和有效性记录。近年来，长效和持续释放形式的GnRHas的可用性大大增加。虽然所有可用的药物似乎都很有希望，但可获得的长期随访和/或比较数据有限。在这次审查中，重要的问题与CPP儿童的治疗进行了讨论。除了评估较新的缓释GnRHa制剂外，还提供了确定哪些儿童应接受治疗的基本因素。突出强调了临床管理中的突出不确定性，并确定了未来需要研究的领域。在PubMed和奥维德中进行了本综述的文献检索，重点是使用术语“中枢性性早熟”和“治疗”的英文出版物。“版权所有（C）2019内分泌学会
Long-acting analogs of GnRH (GnRHas) have been the gold-standard treatment of central precocious puberty (CPP) worldwide and have an enviable track record of safety and efficacy. Recent years have witnessed much growth in the availability of longer-acting and sustained-release forms of GnRHas. Although all available agents appear promising, limited long-term follow-up and/or comparative data are available. In this review, important issues pertaining to the treatment of children with CPP are discussed. In addition to an assessment of the newer extended-release GnRHa formulations, a delineation of factors essential in determining which children should be treated is offered. Outstanding uncertainties in clinical management are highlighted and areas in need of future research identified. Literature searches for this review were performed in PubMed and OVID, with a focus on English-language publications using the terms "central precocious puberty" and "treatment." Copyright (C) 2019 Endocrine Society